These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 3563968)

  • 21. Initiating warfarin therapy: 5 mg versus 10 mg.
    Eckhoff CD; Didomenico RJ; Shapiro NL
    Ann Pharmacother; 2004 Dec; 38(12):2115-21. PubMed ID: 15522981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.
    Neal JM; Kunze KL; Levy RH; O'Reilly RA; Trager WF
    Drug Metab Dispos; 2003 Aug; 31(8):1043-8. PubMed ID: 12867493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients.
    McAleer SD; Foondun AS; Feely M; Chrystyn H
    Chirality; 1997; 9(1):13-6. PubMed ID: 9094197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Warfarin dosage predictions assisted by the analog computer.
    Carter BL; Barr W; Rock W; Taylor JW
    Ther Drug Monit; 1988; 10(1):69-73. PubMed ID: 3376184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.
    Holford NH
    Clin Pharmacokinet; 1986; 11(6):483-504. PubMed ID: 3542339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictability of warfarin dose requirements: theoretical considerations.
    Sawyer WT
    J Pharm Sci; 1979 Apr; 68(4):432-4. PubMed ID: 438962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of warfarin at steady state.
    Routledge PA; Chapman PH; Davies DM; Rawlins MD
    Br J Clin Pharmacol; 1979 Sep; 8(3):243-7. PubMed ID: 497091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination.
    Almog S; Shafran N; Halkin H; Weiss P; Farfel Z; Martinowitz U; Bank H
    Eur J Clin Pharmacol; 1985; 28(3):257-61. PubMed ID: 4007030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic optimization of warfarin therapy.
    Doi SA
    Clin Pharmacol Ther; 1994 May; 55(5):597-601. PubMed ID: 8181204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Maintenance dosage of anticoagulants (warfarin). Calculation on the basis of initial effect].
    Lyduch S; Ovesen L
    Ugeskr Laeger; 1987 Jul; 149(29):1945-7. PubMed ID: 3433414
    [No Abstract]   [Full Text] [Related]  

  • 31. A pocket calculator program for prediction of warfarin maintenance dose.
    Canaday BR; Sawyer WT
    Comput Biol Med; 1982; 12(2):179-87. PubMed ID: 7105664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Warfarin and the grey squirrel.
    Chambers CM; Chambers PL
    Arch Toxicol Suppl; 1983; 6():214-21. PubMed ID: 6578724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Warfarin.
    Benya TJ; Adler DS; Bates TR
    J Am Pharm Assoc; 1976 May; 16(5):271-4. PubMed ID: 1270740
    [No Abstract]   [Full Text] [Related]  

  • 34. Prediction of maintenance warfarin dosage from initial patient response.
    Carter BL; Reinders TP; Hamilton RA
    Drug Intell Clin Pharm; 1983 Jan; 17(1):23-6. PubMed ID: 6825554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-linear multicompartment model for drug binding by extracellular proteins with an application to warfarin.
    Julkunen RJ; Kekki M; Himberg JJ; Wahlström B
    Acta Pharmacol Toxicol (Copenh); 1976 Feb; 38(2):90-103. PubMed ID: 946381
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug-gene interactions: inherent variability in drug maintenance dose requirements.
    Westervelt P; Cho K; Bright DR; Kisor DF
    P T; 2014 Sep; 39(9):630-7. PubMed ID: 25210416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Warfarin maintenance dose Prediction for Patients undergoing heart valve replacement- a hybrid model with genetic algorithm and Back-Propagation neural network.
    Li Q; Tao H; Wang J; Zhou Q; Chen J; Qin WZ; Dong L; Fu B; Hou JL; Chen J; Zhang WH
    Sci Rep; 2018 Jun; 8(1):9712. PubMed ID: 29946101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction.
    Carlquist JF; Horne BD; Mower C; Park J; Huntinghouse J; McKinney JT; Muhlestein JB; Anderson JL
    J Thromb Thrombolysis; 2010 Oct; 30(3):358-64. PubMed ID: 20499136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing.
    Carlquist JF; McKinney JT; Nicholas ZP; Clark JL; Kahn SF; Horne BD; Muhlestein JB; May HT; Anderson JL
    J Thromb Thrombolysis; 2008 Aug; 26(1):1-7. PubMed ID: 17661181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.